Excellent
Mostly Aligned
Patient Risk:
Low
Summary
The response’s claim is directly supported by the label section 5.1 (higher rates vs placebo) and includes label-consistent monitoring and action language.
Category Scores
Accurate Statements
Increased suicidal thoughts and behaviors with Qelbree.
Supported by FDA label section 5.1 Suicidal Thoughts and Behaviors: higher rates in pediatric and adult ADHD patients treated with Qelbree vs placebo, with monitoring and potential regimen change/discontinuation guidance.
Closely monitor Qelbree-treated patients for clinical worsening and emergence of suicidal thoughts and behaviors, especially during initial months and dosage changes.
Label section 5.1: “Closely monitor all Qelbree-treated patients…” and “especially during the initial few months… and at times of dosage changes.”
Consider changing the therapeutic regimen, including possibly discontinuing Qelbree, in patients experiencing emergent suicidal thoughts and behaviors or potential precursors.
Label section 5.1: “Consider changing the therapeutic regimen, including possibly discontinuing Qelbree…”
The response indicates the pediatric population is relevant for monitoring suicidal thoughts and behaviors.
Label section 8.4 Pediatric Use: patients should be monitored for suicidal thoughts and behavior (cross-referenced to 5.1).
Unsupported Statements
The response states: “suicidal thoughts and behaviors” is a boxed warning.
The provided label excerpt shows this content under Warnings and Precautions (5.1) with boxed-warning language referenced, but the response does not substantiate that this specific statement is part of a boxed warning in the provided text.
The response includes earlier bullet claims about ADHD treatment, mechanism, dosing, and other side effects (e.g., insomnia, headaches, dosage ranges) without citing label sections in the materials provided for this audit.
No FDA label text for those non-suicide-related claims is provided in the prompt’s supplied label excerpts; therefore they cannot be verified against the supplied prescribing information.
The response states: “pregnancy_relevant: 'not_assessed_in_provided_text'.”
This is an assessment rather than a label-supported statement about the drug; it is not substantiated by provided label text.
Contradictions
Important Omissions
No specific quantitative incidence details (e.g., % and N values in pediatric and adult trials) were included in the evaluated response claim narrative.
Importance:
Low
Safety Assessment
Potential Patient Risk:
Low
The evaluated claim and accompanying monitoring/action language align with the label’s suicide-thought/behavior warning content. Any unsupported/uncertain parts relate to non-provided claims rather than the core evaluated warning.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Some included assertions (e.g., boxed-warning classification, and several non-suicide-related drug/mechanism/dosing/side-effect bullets) are not supported by the label text provided in the prompt.
Suggested Improvement
Limit the response strictly to the suicide-related label content shown (5.1/8.4/17) when evaluating this warning, and avoid or properly cite any additional pharmacology, dosing, interaction, or other adverse-effect claims not present in the provided label excerpts.